Skip to main content Skip to main navigation menu Skip to site footer

Satisfaction level of anti-DM medicine in DM patients in primary health service in Yogyakarta

  • Tri Pitara Mahanggoro ,
  • Akrom Akrom ,
  • Titis Indri Wahyuni ,


Introduction: Satisfaction with anti-DM drug therapy can affect the effectiveness of and adherence to treatment in diabetic patients. This study aims to determine the description of satisfaction with anti-DM drug therapy for type 2 D.M. patients in primary care.

Method: The design of this study was a cross-sectional study of D.M. Patients. We included 109 DM Patients Participants. Data is collected from a perspective and carried out by face-to-face interviews using a questionnaire. We used the Therapy satisfaction questionnaire Medicine (TSQM) for assessing satisfaction with anti-DM drug therapy. We performed uni- and bivariate data analysis using the free-to-play version of SPSS. Characteristic of subject and TSQM scores were presented descriptively.

Result: The results of calculations with the help of SPSS version 25 are TSQM mean effectiveness domain 61.583 ± 11.598, side effects domain 54.011 ± 32.340, comfort domain 66.883 ± 8.805, global satisfaction domain 55.715 ± 11.274. Based on the research data, it is known that the level of global satisfaction therapy of D.M. patients in primary health facilities is sufficient.  The lowest therapeutic domain of satisfaction is the domain of side effects, and the highest domain is the domain of satisfaction with comfort in drug therapy.

Conclusion: The level of D.M. patient satisfaction with anti-DM drug therapy is sufficient. Patients need to be educated about the possible emergence of side effects due to drug use.


  1. Veyhe AS, Andreassen J, Halling J, Grandjean P, Skaalum Petersen M, Weihe P. Prevalence of prediabetes and type 2 diabetes in two non-random populations aged 44–77 years in the Faroe Islands. J Clin Transl Endocrinol. 2019 Jun 1;16:100187.
  2. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ, et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19•1 million participants. Lancet. 2017 Jan 7;389(10064):37–55.
  3. Noxon V, Davis-Ajami ML, Lu K, Wu J. Diabetes Education: Patterns and Impact on Medication Adherence. Value Heal. 2015;18(3):A64.
  4. Kurnia AD, Amatayakul A, Karuncharernpanit S. Predictors of diabetes self-management among type 2 diabetics in Indonesia: Application theory of the health promotion model. Int J Nurs Sci. 2017 Jul 10;4(3):260–5.
  5. Cunha M, André S, Granado J, Albuquerque C, Madureira A. Empowerment and Adherence to the Therapeutic Regimen in People with Diabetes. Procedia - Soc Behav Sci [Internet]. 2015;171:289–93. Available from:
  6. Wirawan GBS, Wisnawa ADF, Laksmi Dewi NLPM, Darmayanti NMS, Sari AK. Determinan Perilaku Skrining (Screening) Diabetes Mellitus di Wilayah Kerja Puskesmas Denpasar Barat I dan II dalam Kerangka Health Belief Model. J Med Udayana. 2020;9(1):4–12.
  7. Biadgo B, Melak T, Ambachew S, Baynes HW, Limenih MA, Jaleta KN, et al. The Prevalence of Metabolic Syndrome and Its Components among Type 2 Diabetes Mellitus Patients at a Tertiary Hospital, Northwest Ethiopia. Ethiop J Health Sci. 2018;28(5):645–54.
  8. Hidayati T, Fatimah SN, Iskandar S. Normal fasting blood sugar levels and medication adherence improve the quality of life of type 2 diabetes mellitus patients in primary health facilities. Asian J Pharm Clin Res. 2015;11:427–77.
  9. Akrom A, Darmawan E, Maulida N. Factors relate to the hypercreatininemia event of patients at the risk of metabolic syndrome in Jetis I public health center. Pharmaciana. 2017;7(2):205.
  10. Akrom A, Anggitasari W. Adherence and quality of life among diabetic patients with hypertension. Int J Public Heal Sci. 2018;8(1):14.
  11. Alaofè H, Asaolu I, Ehiri J, Moretz H, Asuzu C, Balogun M, et al. Community Health Workers in Diabetes Prevention and Management in Developing Countries. Ann Glob Heal. 2017 May 1;83(3–4):661–75.
  12. Scribano ML, Caprioli F, Michielan A, Contaldo A, Privitera AC, Bozzi RM, et al. Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn’s Disease. Dig Liver Dis. 2019 May 1;51(5):640–7.
  13. Chang KS, Tsai WH, Tsai CH, Yeh HI, Chiu PH, Chang YW, et al. Effects of Health Education Programs for the Elders in Community Care Centers – Evaluated by Health Promotion Behaviors. Int J Gerontol. 2017 Jun 1;11(2):109–13.
  14. Zyoud SH, Al-Jabi SW, Sweileh WM, Arandi DA, Dabeek SA, Esawi HH, et al. Relationship of treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus: Findings from a cross-sectional study. J Clin Transl Endocrinol. 2015 Jun 1;2(2):66–71.
  15. Regnault A, Balp MM, Kulich K, Viala-Danten M. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. J Cyst Fibros. 2012 Dec 1;11(6):494–501.
  16. Idris H, Hasyim H, Utama F. Analysis of Diabetes Mellitus Determinants in Indonesia: A Study from the Indonesian Basic Health Research 2013. Acta Med Indones. 2017;49(4):291–8.
  17. Abudawood M, Tabassum H, Ansar S, Almosa K, Sobki S, Ali MN, et al. Assessment of gender-related differences in vitamin D levels and cardiovascular risk factors in Saudi patients with type 2 diabetes mellitus. Saudi J Biol Sci. 2018 Jan 1;25(1):31–6.
  18. Bosun-Arije FS, Ling J, Graham Y, Hayes C. A systematic review of factors influencing Type 2 Diabetes Mellitus management in Nigerian public hospitals. Int J Africa Nurs Sci. 2019 Jan 1;11:100151.
  19. International Diabetes Federation. IDF Diabaetes Atlas. 6th Edition. International Diabetes Federation; 2013.
  20. Schwarz PEH, Timpel P, Harst L, Greaves CJ, Ali MK, Lambert J, et al. Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018 Dec 11;72(23):3071–86.
  21. Muhammad HI, Asmawi MZ, Khan NAK. A review on promising phytochemical, nutritional and glycemic control studies on Moringa oleifera Lam. in tropical and sub-tropical regions. Asian Pac J Trop Biomed. 2016 Oct 1;6(10):896–902.
  22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and Management of the Metabolic Syndrome. Circulation. 2005 Oct 25;112(17):2735–52.
  23. Prodjosudjadi W, Suhardjono, Suwitra K, Pranawa, Widiana IGR, Loekman JS, et al. Detection and prevention of chronic kidney disease in Indonesia: Initial community screening. Nephrology. 2009 Oct 1;14(7):669–74.
  24. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Heal. 2019 Oct 1;7(10):e1332–45.

How to Cite

Mahanggoro, T. P., Akrom, A., & Wahyuni, T. I. (2021). Satisfaction level of anti-DM medicine in DM patients in primary health service in Yogyakarta. Bali Medical Journal, 10(3), 1379–1384.




Search Panel

Tri Pitara Mahanggoro
Google Scholar
BMJ Journal

Akrom Akrom
Google Scholar
BMJ Journal

Titis Indri Wahyuni
Google Scholar
BMJ Journal